- Molecular Quantum Solutions received €600,000 in pre-seed fundraising.
- The round was led by Scale Capital, along with Rockstart and Stokbro Invest.
- Molecular Quantum Solutions plans to use the funds to convert the tool stack they have developed into a SaaS solution for the pharmaceutical and chemical industries.
PRESS RELEASE — Rockstart, VC and global early-stage accelerator, announced a joint investment in Molecular Quantum Solutions, a Rockstart Emerging Tech portfolio company. The €600k round was led by Scale Capital, along with Rockstart and Stokbro Invest. With the new funding, Molecular Quantum Solutions (MQS) plans to convert the tool stack they have developed into a SaaS solution for the pharmaceutical and chemical industries.
MQS’s in-house team of quantum physicists, chemical engineers, backend and full-stack developers, and business developers offers powerful computing tools to accelerate R&D efforts in the pharmaceutical, biotech, and chemical sectors. Their cutting-edge tools leverage supercomputers and quantum computing technologies, leveraging computational models and algorithms to quickly and efficiently calculate material and chemical properties. The pharmaceutical and biopharmaceutical industry typically invests between approximately 20 and 60 billion USD in the drug formulation and production scale-up phases. With MQS, users can now screen and evaluate new materials for applications such as batteries, eco-friendly solvents, pharmaceutical drugs and biodegradable plastics without the need for expensive laboratory experiments.
“Over the last three years, we have built a solid infrastructure to run computationally demanding quantum chemical calculations in the cloud and solve industry-relevant use cases. Furthermore, we have developed a new quantum computing method that we have integrated into our classical computation pipeline. We have several ongoing collaborations with quantum computing research institutes and companies. We are now preparing to enter the world market with our suite of cloud products.” — Mark Nicholas Jones, CEO/CTO, Molecular Quantum Solutions
“We are excited to partner with Mark and the team at MQS and help them get to the next stage. We are very impressed with their product and commercial achievements so far, and sincerely believe that their quantum chemistry simulation platform will disrupt the drug formulation space. We think that this company stands out from the competition and that they have a clear value proposition to accelerate the pharmaceutical R&D pipeline. We are so excited to start this work!” — Joachim Schelde, Investment Association, Scale Capital
“Increasing computing power will play a critical role in tackling global problems and shortening time to market can significantly contribute to solving problems worldwide. We are investing in Molecular Quantum Solutions (MQS) to streamline computing power and drive change in Industry 4.0 & advanced analytics development. The MQS team is working relentlessly to build highly complex quantum chemistry solutions in the supercomputing and quantum computing space and we are excited to join their journey from the start.” — Michael Bjørnlund, Managing Partner, Rockstart Emerging Tech:
The Rockstart Emerging Tech Fund is Rockstart’s third fund to launch in 2022. Rockstart Emerging Tech has invested in 11 startups since its launch last year. Other fund investments include Forloop, Nova Money, Insai, Rightstars, Tech2B , Contribe , CatchScan, AuthicLabs , Purple Gaze and Viezo.